Neurocrine Biosciences Inc (NBIX)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell
$123.61
Buy
$123.83
$0.60 (+0.49%)
Prices updated at 29 May 2025, 20:31 EDT
| Prices minimum 15 mins delay
Prices in USD
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Dr. William H. Rastetter,PhD
CEO
Dr. Kyle W. Gano, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,800
Head office
6027 Edgewood Bend Court
San Diego
United States
92130
Key personnel
Owner name | Salary |
---|---|
Dr. Eiry W. Roberts, M.D. Chief Medical Officer | 0.69m |
Mr. Gary A. Lyons Independent Director | 0.07m |
Dr. Kevin C. Gorman,PhD Director | 0.78m |
Mr. Richard F. Pops Independent Director | 0.09m |
Ms. Shalini Sharp Independent Director | 0.10m |
Dr. William H. Rastetter,PhD Chairman of the Board | 0.10m |
Ms. Christine A. Poon Independent Director | 0.08m |
Mr. George J. Morrow Independent Director | 0.08m |
Dr. Stephen A. Sherwin, M.D. Independent Director | 0.09m |
Mr. Eric S. Benevich Chief Commercial Officer | 0.64m |
Mr. Darin M. Lippoldt Chief Legal Officer and Corporate Secretary | - |
Ms. Leslie V. Norwalk, Esq. Independent Director | 0.08m |
Dr. Kyle W. Gano, PhD Director, President and Chief Executive Officer | 0.70m |
Mr. Matthew C. Abernethy Chief Financial Officer and Principal Accounting Officer | 0.68m |
Ms. Julie S. Cooke Chief Human Resources Officer | - |
Ms. Johanna Mercier Independent Director | 0.07m |
Mr. David W. Boyer Chief Corporate Affairs Officer | - |
Dr. Jude Onyia, PhD Chief Scientific Officer | 0.68m |
Dr. Ingrid Delaet, PhD Chief Regulatory Officer | - |
Top 5 shareholders
Owner name | No. of shares |
---|---|
BlackRock Inc | 14,682,394 |
Vanguard Group Inc | 9,941,887 |
BlackRock Fund Advisors | 7,068,243 |
Dodge & Cox | 5,534,624 |
State Street Corp | 4,862,116 |
Director dealings
Date | Action |
---|---|
31 Dec 2024 | - |
31 Dec 2024 | - |
31 Dec 2024 | - |
17 Dec 2024 | - |
17 Dec 2024 | - |
17 Dec 2024 | - |
17 Dec 2024 | - |
17 Dec 2024 | - |
29 Nov 2024 | - |
29 Nov 2024 | - |
29 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
04 Nov 2024 | - |
Please note that past performance is not a reliable indicator of future returns.